Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:18:28.692Z.
Calculation as of: 2026-10-06T21:18:28.692Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7fd3b5d8e417d78924f6cd313032c2aac5600bd184120b35a4860f29c1b1599
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $70.63M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | N/A | 26.91 | 41.68 | 277.63 |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 10.82 | 12.57 | 15.78 | 15.78 |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 0.76 | 0.94 | 0.94 | 0.94 |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A | 70.55 | 70.55 | 70.55 |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
